Human Papillomavirus Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

Human Papillomavirus Market By Type (Tetravalent, Bivalent, Polyvalent, and Others), Disease Indication (Cervical Cancer, Anal Cancer, Vulvar & Vaginal Cancer, Penile Cancer, Oropharyngeal Cancer, and Others), End User (Hospitals & Retail Pharmacies, Government Suppliers, and Others), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

Human Papillomavirus Market size is expected to be valued at USD 4,376.3 million in 2022 and is poised to grow at a significant CAGR of 12.7% over 2022–2028. Human papillomavirus (HPV) infection is a leading cause of secondary malignancies in those who have survived cancer in childhood, especially cervical and anal tumors (HPV). However, HPV vaccination can prevent secondary malignancies in young cancer survivors, and it efficiently avoids the infections that contribute to the cancers. The increasing vaccine supply by international organizations such as UNICEF and WHO is driving the global human papillomavirus market growth. For instance, during the Global Vaccine Summit, GSK, Merck, and other international market players promised to provide a significant supply of vaccine doses to increase immunization against the disease in June 2020. Also, the highly efficient human papillomavirus vaccines drive global market growth. Moreover, the increasing prevalence of various types of cancer, especially cervical cancer, is anticipated to increase the sales of the Human Papillomavirus Vaccine. It is expected to follow the human papillomavirus market trend in the forecasted years. Also, the global market players are positively influencing the global human papillomavirus market growth through mergers, collaborations, and new product launches in this sector. Based on the disease indication, the global market is segmented into cervical cancer, anal cancer, vulvar & vaginal cancer, penile cancer, oropharyngeal cancer, and others. cervical cancer treatment is holding the major human papillomavirus market revenue in 2022 and is expected to maintain its growth in upcoming years. However, limited product offerings by manufacturers may hamper the global human papillomavirus market growth. Geographically, Asia Specific held the major market share in the global human papillomavirus market and is expected to dominate the global market in the forecasted years.

Key Developments:

In Sept 2022, The Central government launched India’s first vaccine against cervical cancer. The quadrivalent Human Papillomavirus vaccine (HPV) has been developed by the Serum Institute of India (SII) and the Department of Biotechnology (DBT).

In Sept 2022, Roche announced the launch of a human papillomavirus (HPV) self-sampling solution in countries accepting the CE mark, expanding access to HPV screening options by enabling patients to collect their samples.

Human Papillomavirus Market

MARKET SUMMARY
-
12.7%
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– 12.7%
  • Largest Market– North American
  • Fastest Growing Market– Asia-Pacific

Human Papillomavirus Market

  • The human papillomavirus market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The human papillomavirus market is segmented based on type, disease indication, end-user, and geography.
Key Players
  • Merck & Co
  • GlaxoSmithKline plc
  • Sanofi
  • Johnson & Johnson
Human Papillomavirus Market Growth

The increasing number of cases of human papillomavirus diseases among the population is the major driver for the growth in the global market. It is increasing the demand for HPV vaccines and drugs. Moreover, private institutions are taking initiatives for the development and distribution of the HPV vaccine and government support and initiatives to control the spread virus. Notable organizations such as UNICEF and WHO are taking initiatives to accelerate the immunization process which will drive the market further in the forecasted years.


Global Got Significant Share

Human Papillomavirus Market

Based on regions, the market share is divided into North America, Asia-pacific, Europe, and the Middle East, and the African region. The human papillomavirus market in the Asia Pacific is likely to hold a significant revenue share in 2022, and, in the following years, it is predicted to increase rapidly. It is due to the increasing cases of cervical cancers and increasing investment by major regional companies. North America is also holding a significant market revenue in the global human papillomavirus market and is expected to maintain the trend in the forecasted years.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2017-2021), and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Human Papillomavirus Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The human papillomavirus market is projected to expand at a CAGR of 12.7% during the forecast period

Merck & Co, GlaxoSmithKline plc, Sanofi, Johnson & Johnson, AstraZeneca, Serum Institute, Bharat Biotech, Xenetic Biosciences, Inovio Pharmaceuticals, Novartis AG, Roche

 

Global is the fastest-growing region for human papillomavirus market


Report

Table Of Content

1. Executive Summary
2. Global Human Papillomavirus Market Introduction
2.1. Global Human Papillomavirus Market – Taxonomy
2.2. Global Human Papillomavirus Market –Definitions
2.2.1. By Type
2.2.2. By Disease Indication
2.2.3. By End User
2.2.4. By Region
3. Global Human Papillomavirus Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Human Papillomavirus Market Dynamic Factors – Impact Analysis
3.6. Global Human Papillomavirus Market – Competition Landscape
3.7. Epidemiology
4. Global Human Papillomavirus Market Analysis, 2017-2021 and Forecast, 2022-2028
4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Human Papillomavirus Market, By Type, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.1. Tetravalent
5.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Bivalent
5.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Polyvalent
5.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Others
5.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
6. Global Human Papillomavirus Market, By Disease Indication, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.1. Cervical Cancer
6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Anal Cancer
6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Vulvar & Vaginal Cancer
6.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Penile Cancer
6.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Oropharyngeal Cancer
6.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Others
6.6.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
7. Global Human Papillomavirus Market, By End User, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.1. Hospitals & Retail Pharmacies
7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Government Suppliers
7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. Global Human Papillomavirus Market Forecast, By Region, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.1. North America
8.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Human Papillomavirus Market – Opportunity Analysis Index, By Type, By Disease Indication, By Application, By End User, and Region, 2022-2028
9. North America Human Papillomavirus Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
9.1. Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Tetravalent
9.1.2. Bivalent
9.1.3. Polyvalent
9.1.4. Others
9.2. Disease Indication Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Cervical Cancer
9.2.2. Anal Cancer
9.2.3. Vulvar & Vaginal Cancer
9.2.4. Penile Cancer
9.2.5. Oropharyngeal Cancer
9.2.6. Others
9.3. End User Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Hospitals & Retail Pharmacies
9.3.2. Government Suppliers
9.3.3. Others
9.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. USA
9.4.2. Canada
9.5. North America Human Papillomavirus Market – Opportunity Analysis Index, By Type, By Disease Indication, By Application, By End User, and Country, 2022-2028
9.6. North America Human Papillomavirus Market Dynamics – Trends
10. Europe Human Papillomavirus Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
10.1. Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Tetravalent
10.1.2. Bivalent
10.1.3. Polyvalent
10.1.4. Others
10.2. Disease Indication Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Cervical Cancer
10.2.2. Anal Cancer
10.2.3. Vulvar & Vaginal Cancer
10.2.4. Penile Cancer
10.2.5. Oropharyngeal Cancer
10.2.6. Others
10.3. End User Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Hospitals & Retail Pharmacies
10.3.2. Government Suppliers
10.3.3. Others
10.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe Human Papillomavirus Market – Opportunity Analysis Index, By Type, By Disease Indication, By Application, By End User, and Country, 2022-2028
10.6. Europe Human Papillomavirus Market Dynamics – Trends
11. Asia-Pacific Human Papillomavirus Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
11.1. Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Tetravalent
11.1.2. Bivalent
11.1.3. Polyvalent
11.1.4. Others
11.2. Disease Indication Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Cervical Cancer
11.2.2. Anal Cancer
11.2.3. Vulvar & Vaginal Cancer
11.2.4. Penile Cancer
11.2.5. Oropharyngeal Cancer
11.2.6. Others
11.3. End User Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Hospitals & Retail Pharmacies
11.3.2. Government Suppliers
11.3.3. Others
11.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Human Papillomavirus Market – Opportunity Analysis Index, By Type, By Disease Indication, By Application, By End User, and Country, 2022-2028
11.6. Asia-Pacific Human Papillomavirus Market Dynamics – Trends
12. Latin America Human Papillomavirus Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
12.1. Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Tetravalent
12.1.2. Bivalent
12.1.3. Polyvalent
12.1.4. Others
12.2. Disease Indication Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Cervical Cancer
12.2.2. Anal Cancer
12.2.3. Vulvar & Vaginal Cancer
12.2.4. Penile Cancer
12.2.5. Oropharyngeal Cancer
12.2.6. Others
12.3. End User Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Hospitals & Retail Pharmacies
12.3.2. Government Suppliers
12.3.3. Others
12.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Human Papillomavirus Market – Opportunity Analysis Index, By Type, By Disease Indication, By Application, By End User, and Country, 2022-2028
12.6. Latin America Human Papillomavirus Market Dynamics – Trends
13. Middle East and Africa Human Papillomavirus Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
13.1. Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Tetravalent
13.1.2. Bivalent
13.1.3. Polyvalent
13.1.4. Others
13.2. Disease Indication Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Cervical Cancer
13.2.2. Anal Cancer
13.2.3. Vulvar & Vaginal Cancer
13.2.4. Penile Cancer
13.2.5. Oropharyngeal Cancer
13.2.6. Others
13.3. End User Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Hospitals & Retail Pharmacies
13.3.2. Government Suppliers
13.3.3. Others
13.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. South Africa
13.4.3. Rest of MEA
13.5. MEA Human Papillomavirus Market – Opportunity Analysis Index, By Type, By Disease Indication, By Application, By End User, and Country, 2022-2028
13.6. MEA Human Papillomavirus Market Dynamics – Trends
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Key Types, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Merck & Co
14.2.2. GlaxoSmithKline plc
14.2.3. Sanofi
14.2.4. Johnson & Johnson
14.2.5. AstraZeneca
14.2.6. Serum Institute
14.2.7. Bharat Biotech
14.2.8. Xenetic Biosciences
14.2.9. Inovio Pharmaceuticals
14.2.10. Novartis AG
14.2.11. Roche
15. Research Methodology
16. Key Assumptions and Acronyms

Report

Company Profile

  • Merck & Co
  • GlaxoSmithKline plc
  • Sanofi
  • Johnson & Johnson
  • AstraZeneca
  • Serum Institute
  • Bharat Biotech
  • Xenetic Biosciences
  • Inovio Pharmaceuticals
  • Novartis AG
  • Roche

Description

Human Papillomavirus Market size is expected to be valued at USD 4,376.3 million in 2022 and is poised to grow at a significant CAGR of 12.7% over 2022–2028. Human papillomavirus (HPV) infection is a leading cause of secondary malignancies in those who have survived cancer in childhood, especially cervical and anal tumors (HPV). However, HPV vaccination can prevent secondary malignancies in young cancer survivors, and it efficiently avoids the infections that contribute to the cancers. The increasing vaccine supply by international organizations such as UNICEF and WHO is driving the global human papillomavirus market growth. For instance, during the Global Vaccine Summit, GSK, Merck, and other international market players promised to provide a significant supply of vaccine doses to increase immunization against the disease in June 2020. Also, the highly efficient human papillomavirus vaccines drive global market growth. Moreover, the increasing prevalence of various types of cancer, especially cervical cancer, is anticipated to increase the sales of the Human Papillomavirus Vaccine. It is expected to follow the human papillomavirus market trend in the forecasted years. Also, the global market players are positively influencing the global human papillomavirus market growth through mergers, collaborations, and new product launches in this sector. Based on the disease indication, the global market is segmented into cervical cancer, anal cancer, vulvar & vaginal cancer, penile cancer, oropharyngeal cancer, and others. cervical cancer treatment is holding the major human papillomavirus market revenue in 2022 and is expected to maintain its growth in upcoming years. However, limited product offerings by manufacturers may hamper the global human papillomavirus market growth. Geographically, Asia Specific held the major market share in the global human papillomavirus market and is expected to dominate the global market in the forecasted years.

Key Developments:

In Sept 2022, The Central government launched India’s first vaccine against cervical cancer. The quadrivalent Human Papillomavirus vaccine (HPV) has been developed by the Serum Institute of India (SII) and the Department of Biotechnology (DBT).

In Sept 2022, Roche announced the launch of a human papillomavirus (HPV) self-sampling solution in countries accepting the CE mark, expanding access to HPV screening options by enabling patients to collect their samples.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX